Turkish Journal of Medical Sciences
Volume 34

Number 6

Article 3

1-1-2004

Analysis of Borrelia Burgdorferi Antibody Seroprevalence in
Patients with Behçet´s Disease Using 3 Different Serological
Assays
ERGİN AYAŞLIOĞLU
EMEL ERKEK
SEDAT KAYGUSUZ
DİLEK KILIÇ
ALİ İNAL

See next page for additional authors

Follow this and additional works at: https://journals.tubitak.gov.tr/medical
Part of the Medical Sciences Commons

Recommended Citation
AYAŞLIOĞLU, ERGİN; ERKEK, EMEL; KAYGUSUZ, SEDAT; KILIÇ, DİLEK; İNAL, ALİ; and KESKİN, GÖKSAL
(2004) "Analysis of Borrelia Burgdorferi Antibody Seroprevalence in Patients with Behçet´s Disease Using
3 Different Serological Assays," Turkish Journal of Medical Sciences: Vol. 34: No. 6, Article 3. Available at:
https://journals.tubitak.gov.tr/medical/vol34/iss6/3

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for
inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more
information, please contact academic.publications@tubitak.gov.tr.

Analysis of Borrelia Burgdorferi Antibody Seroprevalence in Patients with
Behçet´s Disease Using 3 Different Serological Assays
Authors
ERGİN AYAŞLIOĞLU, EMEL ERKEK, SEDAT KAYGUSUZ, DİLEK KILIÇ, ALİ İNAL, and GÖKSAL KESKİN

This article is available in Turkish Journal of Medical Sciences: https://journals.tubitak.gov.tr/medical/vol34/iss6/3

Turk J Med Sci
34 (2004) 375-378
© TÜB‹TAK

EXPERIMENTAL / LABORATORY STUDIES

Analysis of Borrelia Burgdorferi Antibody Seroprevalence
in Patients with Behçet’s Disease Using 3 Different
Serological Assays

Ergin AYAfiLIO⁄LU1, Emel ERKEK2, Sedat KAYGUSUZ1, Dilek KILIÇ1, Ali ‹NAL3, Göksal KESK‹N3
1

Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, K›r›kkale University, K›r›kkale - Turkey
2

Department of Dermatology, Faculty of Medicine, K›r›kkale University, K›r›kkale - Turkey

3

Department of Clinical Immunology and Rheumatology, Social Security Hospital, Ankara - Turkey

Received: May 12, 2004

Abstract: Behçet's disease is a chronic multisystemic inflammatory vasculitis of unknown etiology. Various infectious agents have
been implicated as potential triggering factors in the pathogenesis of the disease. The present study was designed to evaluate the
seroprevalence of Borrelia burgdorferi antibodies in Turkish patients with Behçet’s disease.
For this purpose, 90 consecutive patients with Behçet’s disease and 50 healthy individuals were enrolled into a prospective study.
The IgM and IgG antibodies to B. burgdorferi in sera were determined by 3 different serological techniques, namely indirect
immunofluorescence assay (IFA), enzyme linked immunosorbent assay (ELISA) and Western blotting (WB).
Although there was a tendency in the patient group toward a higher seropositivity rate using the ELISA and WB tests, statistical
analysis revealed no difference in antibody prevalence between the patient and control groups for each technique performed (P >
0.05 for all 3 assays).
The findings of the present study do not support a potential role for B. burgdorferi in the etiopathogenesis of Behçet’s disease, at
least in the geographical region of central Anatolia.
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Introduction
Behçet's disease (BD) is a chronic multisystemic
inflammatory disorder characterized by periodic
exacerbations and progressive deterioriation. The disease
most often presents with recurrent orogenital aphthous
ulcerations, uveitis, and skin manifestations like erythema
nodosum, folliculitis and acneiform lesions. Progressive
disease may involve the arthritic, vascular, intestinal and
neurological systems (1,2). The etiology and
pathogenesis of BD are unknown, but a complex
interaction of genetic and enviromental factors seems to
be responsible for immunological dysregulation and
inflammation. Various infectious agents have been
postulated as triggering factors for BD (3,4).

Lyme disease (LD) is an infectious multisystemic
disorder caused by a spirochete, Borrelia burgdorferi.
The disease may affect several organ systems such as the
skin, joints, the central nervous system and the
cardiovascular system (5,6). Because of the wide
spectrum of clinical manifestations in symptomatic
infection, LD can mimic several other systemic disorders.
Of interest is the fact that LD has been initially described
in children with juvenile rheumatoid arthritis (7).
Recently, a role for B. burgdorferi has been proposed
in the etiopathogenesis of BD (8). The aim of this study
was to evaluate the seroprevalence of B. burgdorferi
antibodies among Turkish patients with BD and to
compare the results with those of healthy subjects.
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Materials and Methods
Patient and control groups
Serum samples from 90 patients with BD and 50
adult volunteer blood donors were collected between July
1998 and December 2002. Patients and controls were
from the same geographical area. The diagnosis of BD
was based on the criteria of the International Study
Group for Behçet's Disease (9). Disease activity was based
on clinical findings at the time of venipuncture. Patients
lacking any clinical signs were categorized as having
inactive disease (42 patients; 46.7%). Patients with
major oral aphthae and genital ulcerations, arthritis,
ocular or neurologic manifestations and/or vascular
manifestations constituted the group with active disease
(48 patients; 53.3%). Clinical symptoms of patients with
active BD are shown in Table 1. At the time of the study,
69 patients were taking colchicine and/or non-steroidal
anti-inflammatory drugs. Nine patients were additionally
receiving second line drugs, namely prednisolone,
salazopyrin, azathioprine or cyclosporine. Seven patients
with inactive disease and 5 patients who had received
their initial diagnosis recently were taking no drugs. Fifty
healthy individuals of a similar gender ratio and age range
were assigned as the control group.
Serological Assays for B. burgdorferi Antibodies
Serum IgM and IgG antibodies to B. burgdorferi were
measured by 3 serological techniques: enzyme-linked
immunosorbent
assay
(ELISA),
indirect
immunofluorescence assay (IFA) and Western blot (WB)
test. Test procedures were performed according to the
manufacturer’s protocol (Euroimmun, Luebeck,
Table 1. Clinical symptoms of patients with Behçet’s disease (n = 90).

Germany). Appropriate positive and negative serum
samples, as provided by the manufacturers, served as
internal controls in all serological assays to improve the
reliability of the test procedures.
ELISA: In the first reaction step, diluted patient
samples were incubated with wells coated with antigen
extracts of B. burgdorferi and Borrelia afzelii. To detect
the bound Borrelia-specific IgG or IgM antibodies, a
second incubation was carried out using enzyme-labeled
anti-human antibodies. Values above the recommended
cut-off value of 20 relative units (RU)/ml were considered
positive.
IFA: In order to prevent false positive IgM results,
immunoabsorption was applied before testing with IFA. A
smear of B. burgdorferi covering the reaction areas of a
BIOCHIP slide was incubated with a diluted serum
sample. In a second step, the attached Borrelia-specific
IgG or IgM antibodies were stained with fluoresceinlabeled anti-human antibodies and positive reactions were
visualized under immunofluorescence microscope. Titers
> 1/ 10 and > 1/ 100 were considered positive for IgM
and IgG immunoreactivities, respectively.
WB: The test kit contains test strips with
electrophoretically separated antigen extracts of B.
burgdorferi. In the initial reaction step, the blot strips
were incubated with diluted patient serum. To detect the
bound Borrelia-specific IgG or IgM antibodies, a second
incubation was carried out using enzyme-labeled antihuman antibodies. The results of the WB test were
interpreted as negative, borderline or positive, according
to the manufacturer’s information sheet. Borderline and
positive IgG or IgM WB test results were considered
indicative of seropositivity for B. burgdorferi antibodies.
Statistical Analysis

Symptom *

N (%)

Oral ulcer

90 (100)

Genital ulcer

81 (90.0)

Papulopustular lesions

38 (42.2)

Erythema nodosum

30 (33.3)

Arthritis

28 (31.1)

Arthralgia

61 (67.8)

Eye lesions

22 (24.4)

Deep vein thrombosis

14 (15.6)

Neurological involvement

2 (2.2)

*All symptoms observed during the course of the disease.
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Statistical analysis was performed on PC using SPSS
for Windows, version 11.0. Chi-square test was utilized
to compare numerical data. A P value ≤ 0.05 was
considered significant.

Results
The study group consisted of 90 patients with BD (47
females, 43 males) with a mean age of 35.99 ± 9.09 and
an age range of 16-54 years. The control group of 50
healthy individuals had a comparable age range (18-50
years) and sex ratio (26 females, 24 males).
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IFA, ELISA and WB test results for the patient and
control groups are shown in Table 2. Although there was
a tendency in the patient group toward a higher
seropositivity rate using ELISA and WB, statistical analysis
revealed no significant difference between the patient and
control groups in terms of B. burgdorferi IgG or IgM
seropositivity using ELISA, IFA or WB.

geographical restriction of the disease has been
considered as indirect evidence for a role of infections in
its etiopathogenesis. Several infectious agents have been
speculated to dysregulate the immune system in the
genetically susceptible population of the Silk Road,
leading to the development of BD. Included in this list are
Streptococcus spp., Chlamydia pneumonia, herpes
simplex virus and parvovirus B19 (3,12,13).

Discussion

The first report speculating a potential role for B.
burgdorferi in patients with BD was that by Isogai et al.
(8). The authors investigated the seropositivity rate for B.
burgdorferi antibodies in a Japanese population of 127
patients with uveitis, including those with BD. However,
a recent serological study from the western part of
Turkey by Önen et al. (14) yielded no significant
association between BD and B. burgdorferi infection. The
authors analyzed B. burgdorferi seroprevalence in BD and
detected seropositivity in 26.7% and 13.3% of patients
and 19.4% and 12.9% of healthy controls using ELISA
and WB, respectively.

Lyme disease (LD), is a tick-borne treatable disease,
endemic in some parts of the world. The disease usually
presents with a pathognomonic skin lesion, known as
erythema chronicum migrans. After the dissemination of
the microorganism through blood, the disease secondarily
involves several organ systems such as the skin, nervous
system, joints and heart. The rising incidence and
expanded clinical spectrum make LD an attraction and a
focus of investigations in all medical disciplines. Although
the definitive diagnosis of LD requires the isolation of the
microorganism by culture or demonstration by
polymerase chain reaction, this is not always feasible.
Therefore, diagnosis usually relies on compatible clinical
findings and confirmation by serological assays. Centers
for Disease Control and Prevention recommends a dual
serology approach for the serodiagnosis of B. burgdorferi
infection where WB is utilized as the confirmatory
serological test (10,11).
BD occurs endemically in the eastern Mediterranean
and in Middle and Far Eastern countries, the population
deriving from the ancient Silk Road. The highest
prevalence has been reported in Turkey (4). The

In the present study, 3 different serological methods
were employed to elucidate an association between BD
and B. burgdorferi infection. Although LD is rarely
encountered in Turkey, there is evidence that the Ixodes
ticks harboring B. burgdorferi microorganisms exist in
the country (16). The reported seroprevalence rates for
B. burgdorferi antibodies in the general Turkish
population vary between 2% (in urban areas) and 36%
(in rural areas) depending on the geographical region
(15,16). In our study, the seroprevalence rates for both
patient and control groups were within the range
determined by previous Turkish studies. Although a

Table 2. Antibodies to Borrelia burgdorferi in patients with Behçet’s disease and healthy adult sera as determined
by indirect fluorescent antibody assay (IFA), enzyme-linked immunosorbent assay (ELISA), and Western
immunoblotting (WB).
No. and (%) of positive serum samples
IFA

ELISA

IgG

IgM

Patient Group (90)

9 (10.0%)

1 (1.1%)

Control Group (50)

7 (14.0%)
0.476

p

IgG

WB*
IgM

IgG

IgM

5 (5.6 %) 10 (11.1%)

8 (8.9%)

0

2 (4.0%)

0 (0.0 %)

2 (4.0%)

1 (2.0%)

0

0.258

0.090

0.150

0.111

-

*Positive in 2 and borderline in 6 patients with Behçet’s disease; and borderline in 1 control subject.
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higher seroprevalence rate was detected in patients with
BD using ELISA and WB, comparison with the control
group did not reveal a statistically significant difference.

rather low. Thus, we think that the main statistical
findings of this seroprevalence study would not have been
affected even in the presence of false positive results.

The serologic diagnosis of LD is a challenge. Although
serologic tests, including WB, have several well-defined
limitations, they are frequently employed in
seroprevalence studies and may even be used as
diagnostic tests in patients with compatible clinical
findings (10,17). In the present study, we aimed at
determining the seroprevalence of B. burgdorferi
antibodies in patients with BD using serological testing.
False positivities in serological diagnosis of LD were
reported in patients with several infectious and chronic
inflammatory disorders. In our study, the total number of
positive results with any of the techniques utilized was

In conclusion, these findings do not support a
potential role for B. burgdorferi infection in the
etiopathogenesis of BD, at least in the geographical
region of central Anatolia.

Correspondence author:
Emel ERKEK
Neyzen Tevfik sokak, Ferah apt. 12 / 12
Maltepe 06570
Ankara - Turkey
E-mail: emelerkek@hotmail.com

References
1.

Jorizzo JL, Abernethy JL, White WL et al. Mucocutaneous criteria
for the diagnosis of Behçet’s disease: An analysis of
clinicopathologic data from multiple international centers. J Am
Acad Dermatol 32: 968-76, 1995.

2.

Ayaslioglu E, Erkek E, Kilic D et al. Tetanus antitoxin
seroprevalence in patients with Behcet's disease. Scand J Infect
Dis 35: 299-301, 2003.

3.

Sakane T, Suzuki N, Nagafuchi H. Etiopathology of Behçet’s
disease: immunological aspects. Yonsei Med J 38: 350-8, 1997.

4.

Önder M, Gürer MA. The multiple faces of Behçet’s disease and its
aetiological factors. J Eur Acad Dermatol 15: 126-36, 2001.

5.

Buchstein SR, Gardner P. Lyme disease. Infect Dis Clin North Am
5:103-16, 1991.

6.

Steere AC. Lyme disease. N Engl J Med 321: 586-596, 1989.

7.

Brown SL, Hansen SL, Langone JJ. Role of serology in the
diagnosis of Lyme disease. JAMA 282: 62-6, 1999.

8.

Isogai E, Isogai H, Kotake S et al. Detection of antibodies against
Borrelia burgdorferi in patients with uveitis. Am J Ophthalmol
112: 23-30, 1991.

9.

International Study Group for Behçet's Disease. Criteria for
diagnosis of Behçet's disease. Lancet 335: 1078-80, 1990.

10.

Bunikis J, Barbour AG. Laboratory testing for suspected Lyme
disease. Med Clin North Am 86: 311-40, 2002.

378

11.

Trevejo RT, Krause PJ, Sikand VK et al. Evaluation of the twotest serodiagnostic method for early Lyme disease in clinical
practice. J Infect Dis 179: 931-8, 1999.

12.

Kiraz S, Ertenli I, Benekli M et al. Parvovirus B19 infection in
Behcet's disease. Clin Exp Rheumatol 14: 71-3, 1996.

13.

Ayaslioglu E, Duzgun N, Erkek E et al. Serological evidence of
chronic Chlamydia pneumoniae infection in patients with behçet’s
disease. Scand J Infect Dis 36: 428-30, 2004.

14.

Onen F, Tuncer D, Akar S et al. Seroprevalence of Borrelia
burgdorferi in patients with Behcet's disease. Rheumatol Int 23:
289-93, 2003

15.

Göral G, K›l›cturgay K, Ayd›n L. Antibody prevalence against
Borrelia burgdorferi in some villages in the province of Bilecik. Tr.
J. of Medical Sciences 27: 51-53, 1997.

16.

fien E. Investigations on Lyme Disease in Turkey: Clinical findings,
serological surveys and field studies. 3rd Balkan Conference of
Microbiology, ‹stanbul, September 4-6, 2003. Proceedings and
Abstract Book p: 225.

17.

Huycke MM, D'Alessio DD, Marx JJ. Prevalence of antibody to
Borrelia burgdorferi by indirect fluorescent antibody assay,
ELISA, and western immunoblot in healthy adults in Wisconsin
and Arizona. J Infect Dis 165: 1133-7, 1992.

